BioPharma Resources

Drug Trial Radar · NCT07333352

Phase II Clinical Trial of PCV24 in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of A 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700) in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

480

Actual

Start

Sep 11, 2025

Primary completion

Apr 14, 2026

Study completion Apr 14, 2026

Sponsor

Lead sponsor
Reinovax Biologics Co., LTDIndustry
Sponsor type
Industry
First posted
Jan 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 weeks, up to 71 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months. The purpose of this study is to evaluate the immunogenicity and safety of the 24-valent pneumococcal polysaccharide conjugate vaccine.

Conditions

  • Pneumococcal Infectious Disease

Interventions

  • 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700)Biological

    24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700) consisting of polysaccahrides from 24 pneumococcal serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F conjugated two carrier proteins. Each dose contains 0.5 ml vaccine in a prefilled syringe.

  • 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)Biological

    13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13) consisting of plosaccharides from 13 pneumococcal serotypes: 1, , 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F conjugated CRM197. Each dose contains 0.5 ml vaccine in a prefilled syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with the pneumococcal serotype-specific IgG antibody concentration ≥0.35 μg/ml.Time frame: 30 days post the primary and booster immunization.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Luzhou District Center for Disease Control and Prevention

    Changzhi, Shanxi, China

  • Qinxian County Center for Disease Control and Prevention

    Changzhi, Shanxi, China

  • Kuangqu District Center for Disease Control and Prevention of Yangquan City

    Yangquan, Shanxi, China

  • Xinjiang County Center for Disease Control and Prevention

    Yuncheng, Shanxi, China

  • Jishan County Center for Disease Control and Prevention

    Yuncheng, Shanxi, China

  • Yongji City Center for Disease Control and Prevention

    Yuncheng, Shanxi, China

  • Shangdang District Center for Disease Control and Prevention of Changzhi City

    Yuncheng, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.